
Aims Right heart dysfunction is a common complication in chronic obstructive pulmonary disease (COPD), yet the underlying mechanisms remain poorly understood. Endoscopic lung volume reduction (ELVR) using Zephyr® valves improves lung function by reducing emphysema-induced hyperinflation, providing clinical benefits beyond enhanced pulmonary mechanics. Magnetic resonance imaging studies suggest that alleviating lung hyperinflation may also positively affect left heart function. We hypothesized that ELVR may also improve right heart function. Research question This study evaluated right heart function after ELVR in patients with COPD using invasive pressure-volume loop analysis. Study design and methods Eleven patients with severe COPD underwent baseline right heart catheterization because of suspected pulmonary hypertension, and pressure-volume loop analysis. Eight patients underwent ELVR, followed by right heart function reassessment 12 weeks post-procedure. Results Pre-ELVR, pulmonary artery pressures ranged from 23 to 32 mmHg, vascular resistance was 2.2-4.8 WU, and significant impaired pressure-volume indexes were observed compared to reference data. Post-ELVR, lung hyperinflation improved significantly, with a reduction in the Residual Volume /Total Lung Capacity (RV/TLC) ratio. RV/TLC changes correlated with improvements in end-diastolic pressure-volume relationships (r=0.82, P=0.02) and the time constant of relaxation Tau (r=0.84, P=0.01). Functional outcomes, such as 6-minute walk distance and dyspnea scores, were driven by stroke work and diastolic parameters, respectively. Conclusions In this exploratory single center study, endoscopic lung volume reduction with associated improvement in hyperinflation led to significant improvement in exercise capacity and in right ventricular function.
Introduction Chronic obstructive pulmonary disease is a common lung disease. Acute exacerbations (AECOPD) are associated with increased hospitalisations and mortality. Current guidelines provide only conditional recommendation for the use of High Flow Nasal Cannula (HFNC) supported by low-certainty evidence in hypercapnic respiratory failure. Since then, additional studies have been published, and we aimed to review the available literature on HFNC as a first-line therapy in hypercapnic AECOPD. Methods Structured literature research was performed in PubMed and Embase to include studies assessing HFNC as a first-line therapy in hypercapnic AECOPD and focusing on clinical outcomes (dyspnoea, blood gas, treatment failure, mortality). Studies were categorized as single-arm studies, comparisons with conventional oxygen therapy (COT), or comparisons with non-invasive ventilation (NIV). Results Among 17 articles included, 2 were uncontrolled, 3 articles compared HFNC to COT and 12 compared HFNC to NIV. HFNC was often associated with better comfort and tolerance. Compared to COT, HFNC might reduce treatment failure, but evidence is still scarce. Compared to NIV, HFNC had similar effects on dyspnoea and blood gas analysis in most studies, but it remains uncertain considering treatment failure. Conclusion In hypercapnic AECOPD, HFNC remains an alternative therapeutic option as compared to COT but also to NIV when the latter is contraindicated, not tolerated or during breaks from NIV. Further research is warranted with well-designed RCT focusing on treatment failure and mortality. In the future, patients might be selected considering some endotypes of AECOPD such as bronchorrhea, sleep apnea overlap or disproportionate dyspnoea which could benefit differently from HFNC.